MolNFT v1 · #106779 · protein
Crystal structure of hookworm platelet inhibitor
4TPV: “Crystal structure of hookworm platelet inhibitor”. X-ray diffraction, 3 pockets (best druggability 0.74). MolNFT v1 #106779 on GenesisL1: 3D structure, binding sites and pockets in GL1X.
- PDB
- 4TPV
- Type
- protein
- Length
- 359 residues
- Chains
- 2
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Platelet inhibitor
- UniProt
- Q962V9
- Pockets
- 3 · best druggability 0.74
Structure
x-ray diffraction · 2 distinct chains · 35% helix, 19% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Platelet inhibitor | protein | 182 | 34% helix, 19% strand | Q962V9 |
| B | Platelet inhibitor | protein | 177 | 35% helix, 20% strand | Q962V9 |
Ligands and binding sites
- GOL · Glycerol · additive · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
3 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 79 | 0.74 | 0.97 | 28 | empty |
| 2 | 108 | 0.39 | 0.75 | 17 | empty |
| 3 | 55 | 0.26 | 0.72 | 14 | empty |
Interfaces
1 interface between chains.
- A–B · 1192 Ų buried · 12 hydrogen bonds · protein-protein
Modifications
Observed in the structure: 10 disulfide (disulfide).
Compared structures
- 4TPV · Crystal Structure of Hookworm Platelet Inhibitor · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt Q962V9
- Elsewhere: RCSB PDB 4TPV · PDBe 4TPV · UniProt Q962V9
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.